• SFB 1328

    Adenine Nucleotides in Immunity and Inflammation

  • SFB Retreat 2022 Timmendorfer Strand

  • SFB Retreat 2022 Timmendorfer Strand

  • SFB1328 Retreat 2021

    26th - 28th of May 2021

    read more...

Next Science Afternoon

  • 15 Jan
    Science Afternoon 15.01.2025

    2:00-3:00 pm Meet the speaker for Young Scientist N30

    3:00–3:45 pm Progress Report A18

    Sahra Tajdar, UHH - Synthesis and Optimization of potential…

INTRODUCTION MOVIE

PROJECT MOVIES

For direct access to project movies please click on the following links: A01A02A03A04, A05A06, A07A10, A11A12A13, A14A15, A16, A18, A19, A20 and A21.

SFB1328

Extracellular and intracellular adenine nucleotides (AN) impact on all central processes in biology and medicine. AN are essential and ubiquitous signaling molecules involved in regulating universal cellular processes, including (i) cell-cell communication and (ii) intracellular signaling. 

Unresolved issues regarding the signaling function of extracellular AN in inflammation, e.g. adenosine triphosphate (ATP) or nicotinamide adenine dinucleotide (NAD), relate to the timing and location of their release, their conversion by ecto-enzymes, and their biological role within the balance of inflammatory processes. Likewise, the precise role of intracellular AN second messengers, e.g. nicotinic acid adenine dinucleotide phosphate (NAADP) or 3’,5’-cyclic adenosine monophosphate (cAMP), in the spatio-temporal control of signaling processes by forming or modulating microdomains with their metabolizing enzymes, specific binding proteins or receptors, or target ion channels remains largely unknown. 

The central goal of the research consortium is to further our understanding of the regulatory roles of AN and their kinetics in the context of inflammatory diseases. Specific aims relate to (i) modulation of the balance between pro- and anti-inflammatory processes by AN converting ecto-nucleotidases and purinergic receptors, and to (ii) AN-driven intracellular calcium signaling and cAMP signaling in inflammation.

PAPER

SFB1328 scientists headed by A14 and Z02 just published in Cellular and Molecular Life Sciences the generation of an ENPP1/CD203a heavy-chain antibody, which allowed for the first time the specific expression of ENPP1, a membrane-bound ectonucleotidase, on human immune cells. The work was mainly carried out by Hannah Lorenz, who is a medical doctor student at the IRTG.

PAPER

SFB1328 scientists headed by Chris Meier and Andreas Guse just published in Nature Communications the design, synthesis and validation of the first reliable membrane-permeant precursor of the Ca2+ mobilizing 2nd messenger NAADP (nicotinic acid adenine dinucleotide phosphate). This highly interdisciplinary work of projects A01, A02, A03, A04, and A21 allows exclusive stimulation of the NAADP/Ca2+ signaling pathway without touching any surface receptors that usually couple to multiple signaling systems. Of note, we also developed the inactive control compound, MASTER-NADP, to control for background signals potentially caused by e.g. membrane perturbations or off-target effects of free masking groups formed upon intracellular deprotection of MASTER-NAADP or -NADP.

 

SFB1328 Meeting Report: 2nd European Purine Meeting

From September 4 to 6, 2024 the second European Purine Meeting was held in Ferrara, Italy. It was organized by Francesco di Virgilio and Elena Adinolfi and dedicated to the retirement of Francesco di Virgilio who has greatly developed and influenced P2X7 receptor research, in particular with respect to inflammation and cancer. Two members of the SFB1328, Christa Müller (A11) and Friedrich Koch-Nolte (Z02), were part of the scientific committee of the conference and were presenting the opening plenary lectures. In addition, contributions to symposia were presented by further members of the SFB1328, Annette Nicke (A15), Tim Magnus (A13), Christian Lohr (A07) and, as a junior scientist, Riekje Winzer (A14), who was awarded a prize for the best lecture by a young scientist, sponsored by the journal Purinergic Signaling (Springer).

 

For further announcements see:

LATEST PUBLICATION

Lorenz H, Menzel S, Roshchyna N, Albrecht B, Gebhardt AJ, Schneider E, Haag F, Rissiek B, Oheim R, Koch-Nolte F, Winzer R, Tolosa E. ENPP1/CD203a-targeting heavy-chain antibody reveals cell-specific expression on human immune cells. Cell Mol Life Sci. 2024 Dec 18;82(1):6. doi: 10.1007/s00018-024-05539-y. 

Gerlach F, Möckl F, Kovacevic D, Brock VJ, Winzer R, Meyer L, Lohr D, Woelk LM, Tolosa E, Werner R, Diercks BP. Imaging Initial Ca2+ Microdomains in Primary T Cells. J Vis Exp. 2024 Oct 4;(212). doi: 10.3791/67075. 

Krukenberg S, Möckl F, Weiß M, Dekiert P, Hofmann M, Gerlach F, Winterberg KJ, Kovacevic D, Khansahib I, Troost B, Hinrichs M, Granato V, Nawrocki M, Hub T, Tsvilovskyy V, Medert R, Woelk LM, Förster F, Li H, Werner R, Altfeld M, Huber S, Clarke OB, Freichel M, Diercks BP, Meier C, Guse AH. MASTER-NAADP: a membrane permeable precursor of the Ca2+mobilizing second messenger NAADP. Nat Commun. 2024 Sep 13;15(1):8008.

von Kalben L, Sauer J, Gee C, Hirnet D, Lohr C. Dopaminergic cAMP signaling in mouse olfactory bulb astrocytes. Neurochem Int. 2024 Oct;179:105828.

Koch-Nolte F. Nanobody-based heavy chain antibodies and chimeric antibodies. Immunol Rev. 2024 Aug 30.

 

 

 

Contact

University Medical Center Hamburg-Eppendorf 
Department of Biochemistry and Molecular Cell Biology 
Martinistrasse 52
20246 Hamburg

Scientific Coordinator

Dr. Björn-Philipp Diercks
Fon: +49  (0) 40 7410 54338
E-Mail: b.diercks©uke.de

Administration

Laura Mitsching
Fon: +49  (0) 40 7410 50301
E-Mail: l.mitsching©uke.de